Interpace Biosciences Inc

Interpace Biosciences maintains a strong liquidity position, with a current ratio of 1.94 and no long-term debt, indicating a solid ability to meet short-term obligations. The company's liquidity_fpt score reflects a low liquidity risk, supported by $2.5 million in cash and equivalents and $5.8 million in operating cash flow. This liquidity profile is further reinforced by a debt-to-equity ratio of 0.0, suggesting no leverage risk. Profitability metrics show a return on equity (ROE) of 1.0989 and a return on assets (ROA) of 0.7263, both of which are strong indicators of efficient capital use and asset management. These figures suggest that the company is generating substantial returns relative to its equity and asset base, which is favorable compared to industry norms for diagnostic services. The company's revenue is concentrated in its core diagnostic services, with no disclosed geographic diversification in the provided data. This concentration may expose the company to regional market fluctuations, though the lack of geographic breakdown in the input data limits further analysis. Growth trajectory is positive, with a net income of $24.6 million and a free cash flow of $25.1 million, indicating strong operational performance and cash generation. The outlook for the current fiscal year suggests continued growth, supported by the company's focus on expanding its portfolio of molecular diagnostic tests. Risk factors are minimal, with low liquidity and dilution risk scores. The company has no immediate filing-based liquidity or dilution flags, and the absence of long-term debt reduces financial leverage risk. The dilution potential is also low, with no recent issuance or ATM/shelf disclosures indicating near-term dilution pressure. Recent events include the continued commercialization of its molecular diagnostic tests, with no significant regulatory or operational disruptions reported in the latest filings or transcripts.